HBOC-201

PreclinicalBiologic

JJohns Hopkins University

HBOC-201 is one of 49 biologic programs targeting Blood Transfusion. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Blood TransfusionActive, not recruiting

AnemiaActive, not recruiting

Blood TransfusionPreclinical

Active, not recruiting

AnemiaPreclinical

Active, not recruiting

Competition

Competitive Landscape

75 competitors in Anemia

#DrugCompanyPhaseTrials

Epogen

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Phase 3

52 2

Zemplar

AbbVie

Approved

2 3

Rapamune

PPrism Pharmaceuticals

Approved

3 4

Leustatin

Rayos

Rituxan

2 7

Cytoxan

BBaxter Healthcare Corporation

Phase 3

6 8

Revlimid

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Phase 3

2 9

Campath

GGenzyme, a Sanofi Company

Phase 3

2 10

Imbruvica

PPharmacyclics LLC.

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Anemia2 trials

Expanded Access Study of HBOC-201 (Hemopure) for the Treatment of Life-Threatening Anemia

Enrolling by invitation·EEnglewood Hospital and Medical Center·N/A·NCT01881503·50 enrolled

An Expanded IND Access Investigation of HBOC-201 Infusion in Patients With Severe Acute Anemia Who Are Unable to Receive Red Blood Cell Transfusion

No longer available·MMichael Boisen··NCT03633604

Cardiopulmonary Bypass1 trial

A Study of Hemopure® to Enhance Tissue Preservation During Cardiopulmonary Bypass Surgery

Unknown status·BBiopure Corporation·Phase 2·NCT00301535·60 enrolled

ESS1 trial

Expanded Access Protocol Using HBOC-201

No longer available·JJohns Hopkins University··NCT02684474

Blood Transfusion1 trial

HBOC-201 Expanded Access Protocol for Life-threatening Anemia for Whom Allogeneic Blood Transfusion is Not an Option

No longer available·MMauricio Lynn··NCT02934282

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for HBOC-201. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — HBOC-201 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for HBOC-201. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Johns Hopkins University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Preclinical[1]
Company: JJohns Hopkins University

HBOC-201

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Anemia2 trials

Cardiopulmonary Bypass1 trial

ESS1 trial

Blood Transfusion1 trial

References

Drug Info

Quick Facts

Related News